2 recruiting, 2 terminated, 2 unknown, 2 withdrawn. 11 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Recruiting 2, Terminated 2, Unknown 2, Withdrawn 2, Active not recruiting 1, Completed 1, Suspended 1 |
| Phase 2 | 3 | Recruiting 1, Unknown 1, Withdrawn 1 |
Follow HER-2 Protein Overexpression: new trials by email Literature Review of HER-2 Protein Overexpression trials Research Report on HER-2 Protein Overexpression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC RC48+PD-1+platinum-based - Esophageal Squamous Carcinoma, HER-2 Protein Overexpression | Phase 1 / Phase 2 | Unknown | Changhai Hospital | 20 | 2023-09-30 | 2023-09-26 |
| Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations Axitinib - Breast Cancer, Ovarian Cancer | Phase 1 | Completed | Lynkcell Europe | 10 | 2023-07-11 | 2024-12-30 |
| PRE-ISPY Phase I/II Oncology Platform Program ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab - HER2-positive Breast Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 280 | 2023-02-15 | 2026-09-30 |
| Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors ORM-5029 - HER2-positive Breast Cancer, HER-2 Protein Overexpression | Phase 1 | Terminated | Orum Therapeutics USA, Inc. | 25 | 2022-10-03 | 2025-07-04 |
| HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma T cells or CAR T cells, Pembrolizumab Injectable Product, Nivolumab Injectable Product - Sarcoma, HER-2 Protein Overexpression | Phase 1 | Recruiting | Baylor College of Medicine | 25 | 2021-12-07 | 2026-01-22 |
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Vic-trastuzumab duocarmazine (SYD985) + paclitaxel - HER2-positive Breast Cancer, HER2 Low | Phase 1 | Withdrawn | QuantumLeap Healthcare Collaborative | 2021-07-28 | 2023-11-18 | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers SNK01, Trastuzumab, Cetuximab - Advanced Solid Tumor, Metastatic Cancer | Phase 1 / Phase 2 | Withdrawn | NKGen Biotech, Inc. | 2021-03-01 | 2021-05-12 | |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors CT-0508, Pembrolizumab - HER2-positive, Adenocarcinoma | Phase 1 | Unknown | Carisma Therapeutics Inc | 48 | 2021-02-02 | 2024-12-18 |
| Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors chimeric antigen receptor (CAR) T cell therapy - HER-2 Gene Amplification, HER2-positive Gastric Cancer | Phase 1 | Suspended | Bellicum Pharmaceuticals | 220 | 2020-12-07 | 2023-04-20 |
| Testing a New Imaging Agent to Identify Cancer 89Zr-ss-pertuzumab PET/CT - HER-2 Positive Malignant Carcinoma of Breast, HER-2 Protein Overexpression | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2020-11-30 | 2026-07-13 |
| Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers ACTR T Cell Product, Trastuzumab - Solid Tumor, HER-2 Protein Overexpression | Phase 1 | Terminated | Cogent Biosciences, Inc. | 6 | 2019-03-13 | 2020-03-31 |
Breast Neoplasms (7) · Neoplasm Metastasis (4) · Ovarian Neoplasms (4) · Stomach Neoplasms (4) · Colorectal Neoplasms (3) · Endometrial Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Urinary Bladder Neoplasms (3) · Adenocarcinoma (2) · Carcinoma, Non-Small-Cell Lung (2) · Neoplasms (2) · Pancreatic Neoplasms (2) · Sarcoma (2) · Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1)
Breast Diseases (7) · Neoplasms by Site (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Neoplasms (6) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Neoplasms by Histologic Type (5) · Adnexal Diseases (4) · Carcinoma (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Female Urogenital Diseases (4)
Trastuzumab (2) · ALX148 (1) · Automobiles (1) · Axitinib (1) · Cetuximab (1) · Immune Checkpoint Inhibitors (1) · Immunotherapy, Adoptive (1) · Paclitaxel (1) · Receptors, Chimeric Antigen (1) · pembrolizumab (1) · trastuzumab duocarmazine (1) · tucatinib (1) · zanidatamab (1)
QuantumLeap Healthcare Collaborative (2) · Baylor College of Medicine (1) · Bellicum Pharmaceuticals (1) · Carisma Therapeutics Inc (1) · Changhai Hospital (1) · Cogent Biosciences, Inc. (1) · Lynkcell Europe (1) · Memorial Sloan Kettering Cancer Center (1) · NKGen Biotech, Inc. (1) · Orum Therapeutics USA, Inc. (1)
United States (8) · Ukraine (1)
Paula R Pohlmann, MD, MSc, PhD (2) · Anthony Elias, MD (1) · Glen Weiss, MD (1) · Jeanett Wetzel (1) · Meenakshi Hegde, MD (1) · Nabil Ahmed, MD (1) · Paul Y. Song, MD (1) · Shoba Navai, MD (1) · Somali Gavane, MD (1)
PMID 36441083, PMID 36449446, PMID 38272704, PMID 39726590, PMID 39920391
R01CA276684 (1)